BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 15466213)

  • 1. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.
    Sacchi A; Gasparri A; Curnis F; Bellone M; Corti A
    Cancer Res; 2004 Oct; 64(19):7150-5. PubMed ID: 15466213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
    Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
    Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice.
    Comes A; Di Carlo E; Musiani P; Rosso O; Meazza R; Chiodoni C; Colombo MP; Ferrini S
    Eur J Immunol; 2002 Jul; 32(7):1914-23. PubMed ID: 12115611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response.
    Seynhaeve AL; Hoving S; Schipper D; Vermeulen CE; de Wiel-Ambagtsheer Ga; van Tiel ST; Eggermont AM; Ten Hagen TL
    Cancer Res; 2007 Oct; 67(19):9455-62. PubMed ID: 17909055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of IFN-gamma in Bacillus Calmette-Guérin-induced but not in tumor-induced sensitization to TNF-induced lethality.
    Cauwels A; Brouckaert P; Grooten J; Huang S; Aguet M; Fiers W
    J Immunol; 1995 Mar; 154(6):2753-63. PubMed ID: 7876546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of IFN-gamma production by TNF-alpha in macrophages from the tumor environment: significance as an angiogenic switch.
    Lee H; Baek S; Joe SJ; Pyo SN
    Int Immunopharmacol; 2006 Jan; 6(1):71-8. PubMed ID: 16332515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.
    Curnis F; Sacchi A; Corti A
    J Clin Invest; 2002 Aug; 110(4):475-82. PubMed ID: 12189241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer.
    Bertilaccio MT; Grioni M; Sutherland BW; Degl'Innocenti E; Freschi M; Jachetti E; Greenberg NM; Corti A; Bellone M
    Prostate; 2008 Jul; 68(10):1105-15. PubMed ID: 18437689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of STAT1/IRF-1 on synergistic ROS production and loss of mitochondrial transmembrane potential during hepatic cell death induced by LPS/d-GalN.
    Lee HJ; Oh YK; Rhee M; Lim JY; Hwang JY; Park YS; Kwon Y; Choi KH; Jo I; Park SI; Gao B; Kim WH
    J Mol Biol; 2007 Jun; 369(4):967-84. PubMed ID: 17475277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antitumor effects of tumor necrosis factor and gamma-interferon on human colon carcinoma cell lines.
    Schiller JH; Bittner G; Storer B; Willson JK
    Cancer Res; 1987 Jun; 47(11):2809-13. PubMed ID: 3105867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation of antimetastatic activity of interferon and tumor necrosis factor by heparin.
    Sylvester DM; Liu SY; Meadows GG
    Immunopharmacol Immunotoxicol; 1990; 12(2):161-80. PubMed ID: 2121817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
    Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vivo anti-tumour efficacy of tumour necrosis factor and interferon- alpha, -gamma on human renal cell carcinoma heterotransplanted in nude mice].
    Onishi T; Machida T; Masuda F; Iizuka N; Nakauchi K; Furuta N; Shirakawa H
    Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1571-8. PubMed ID: 2121869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice.
    Talmadge JE; Tribble HR; Pennington RW; Phillips H; Wiltrout RH
    Cancer Res; 1987 May; 47(10):2563-70. PubMed ID: 3105865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).
    Curnis F; Sacchi A; Borgna L; Magni F; Gasparri A; Corti A
    Nat Biotechnol; 2000 Nov; 18(11):1185-90. PubMed ID: 11062439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming.
    Romieu-Mourez R; François M; Abate A; Boivin MN; Birman E; Bailey D; Bramson JL; Forner K; Young YK; Medin JA; Galipeau J
    Cancer Res; 2010 Oct; 70(20):7742-7. PubMed ID: 20924101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of cytotoxic activity of recombinant human tumor necrosis factor (rHu-TNF) by recombinant human interferon-gamma (rHu-IFN-gamma).
    Taguchi T; Kimoto Y; Tanji Y; Abe S; Nakano K; Sohmura Y
    J Biol Response Mod; 1987 Dec; 6(6):599-609. PubMed ID: 3131488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
    Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
    J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
    Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH
    Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.